• E-mail
• Print
• RSS

Study: MRSA better treated with Zyvox than vancomycin

Infection Control Monitor, June 3, 2005

The antibiotic Zyvox is more effective at treating, and preventing the spread of, methicillin-resistant Staphylococcus aureus (MRSA) than the popular antibiotic vancomycin, according to a large MRSA study published in Antimicrobial Agents and Chemotherapy.

The study examined 1,180 patients with complicated skin and soft tissue infections, 361 of whom were infected with MRSA. The study found that Zyvox patients enjoyed an 88.6% microbiologic cure rate as opposed to a 66.9% cure rate for vancomycin patients.

Additionally, Zyvox patients had five fewer days of intravenous therapy than vancomycin patients.

MRSA, a multidrug-resistant infection on the rise in both community and hospital settings, is a common cause of morbidity. Thirty years ago, only 2% of healthcare-acquired Staph infections in intensive care units were resistant to antibiotics. Today, approximately 60% of infections are resistant.

• E-mail to a Colleague
• Print
• RSS
• Archive